cox2 is up-regulated with inflammation. Activation of macrophages is associated with up-regulation of cox2 and synthesis of PGE2, 10 and human studies have documented increased PGE2 synthesis associated with the cox2 isoform in macrophages in human AAA tissue. 11 Based on these observations, we proposed that blocking cox activity could potentially slow AAA development. Fortuitously, there is a class of drugs, nonsteroidal anti-inflammatory drugs (NSAIDs), that inhibits both cox1 and cox2 activity.
The rat isolated aortic elastase perfusion model has been proven to be a useful model, and the time course of aneurysm formation has been well characterized. 12, 13 There is an initial dilatation of the aorta associated with the perfusion, and subsequent aneurysmal degeneration begins on about day 4 and continues to day 14 . In a small preliminary study with this animal model, indomethacin, an NSAID, was shown to significantly attenuate aneurysmal expansion in the initial 7-day postperfusion period. 14 The purpose of this study was to determine if indomethacin's effects would be sustained in a longer time course and to determine the molecular basis of its effects.
METHODS

Aortic perfusion.
Adult male Wistar rats, weighing 350 to 400 g, were cared for in accordance with a protocol approved by the Washington University School of Medicine Animal Studies Committee. Each rat in the study underwent isolated aortic perfusion as described by Anidjar et al 12 and as used in other studies from this laboratory. 7, 14 In brief, rats were anesthetized with 6% pentobarbital (0.1 mL/100 g body weight), and a laparotomy was performed under sterile conditions. The infrarenal abdominal aorta was dissected free of the inferior vena cava, followed by ligation of the inferior mesenteric artery and all lumbar branches of the aorta caudal to the left renal vein. Through a separate groin incision, a PE10 polyethylene catheter (Baxter, McGraw Park, Ill) was introduced into the femoral artery and advanced into the distal infrarenal aorta. An atraumatic clamp was placed on the aorta just below the level of the left renal vein, and a silk ligature encompassing the distal aorta and the catheter within it was secured just above the aortic bifurcation, thus isolating the catheter tip within the infrarenal aorta. This isolated segment was perfused continuously for 2 hours at 100 mm Hg with 2 mL of volume by means of a syringe pump (Sage Instruments, Boston, Mass). A total of 195 rats underwent isolated aortic perfusion. Forty were perfused with saline only, and these served as controls.
The remaining 155 rats underwent perfusion with 25 U/mL porcine pancreatic elastase (type I, Sigma). After perfusion was completed, the catheter was withdrawn, the femoral artery was ligated, and flow was restored in the infrarenal aorta. Preperfusion and postperfusion aortic diameters were measured in situ under physiologic conditions by means of a micrometer with magnification. The wound was closed, and each animal was kept in an individual cage. Animals were killed by lethal overdose of pentobarbital at predetermined endpoints of 2, 4, 7, 14, or 28 days. Before the rats were killed, another laparotomy was performed and aortic diameters were again measured in situ under physiologic pressure. Aortas were either perfusion-fixed in situ for histologic studies with 10% neutral buffered formalin at 120 mm Hg for 10 minutes, excised, and snap frozen for later biochemical analyses, or excised and used immediately for aortic whole organ culture.
Drug treatment. After aortic perfusion, the elastase-perfused animals were divided into two groups. The rats in the first group received no treatment (n = 82). In the second group, each animal received daily subcutaneous injections of 1.6 mg/kg of indomethacin, beginning after aortic perfusion and continuing until the animal was killed. The animals were not pretreated with indomethacin before aortic perfusion.
Aortic organ cultures. A segment of freshly harvested aorta was divided into two small pieces, each approximately 2 mm long. Each segment was placed into a separate well of six-tissue culture plates. The specimens were allowed to adhere to the tissue culture plates, then each well was supplemented with 1.5 mL of culture medium, and the plates were incubated at 37°C in a humidified 5% CO 2 atmosphere. After 72 hours, the conditioned media was collected and stored at -20°C, until they were used for enzyme-linked immunosorbent assay (ELISA) or substrate gel zymography.
Enzyme-linked immunosorbent assay. For the assay, the pooled culture media for each aorta was assayed. PGE2 was quantified by means of competitive-binding indirect ELISA, as previously described. 11 Each sample was measured in triplicate. Standard curves were included in each assay.
Histology. Perfusion-fixed aortas were immersed in 10% neutral buffered formalin overnight at 4°C, dehydrated through graded ethanols, and embedded in paraffin. Specimens were cut in cross section at 5 µm and attached to glass slides. Sections were stained with Verhoeff-van Gieson for elastin and with hematoxylin and eosin for routine histological examination. May 1999 Immunohistochemistry. Paraffin-embedded sections were also used for immunohistochemistry. The sections were deparaffinized and rehydrated, and endogenous peroxidase activity was quenched by incubation with 0.3% H 2 O 2 at room temperature for 30 minutes. Sections were then incubated with appropriate antibodies, anti-PGE2, anti-ED2 antigen (for macrophages), anti-cox2, or anti-MMP-9 antibodies, or with 10% horse serum (control). The immune complexes were detected by means of immunoperoxidase staining with a Vectastain Elite kit (Vector Laboratories, Burlingame, Calif). The sections were then counterstained in preparation for histologic analysis.
Substrate gel zymography. Aortic culture media were normalized to total protein, mixed with nonreducing sodium dodecyl sulfate sample buffer, and resolved by electrophoresis through 10% polyacrylamide gels co-polymerized with 1 mg/mL gelatin (Sigma, St. Louis, Mo), as previously described. 15 The gels were incubated overnight at 37°C in 50 mmol/L Tris-HCl, pH 8.5, containing 5 mmol/L CaCl 2 and 0.2% NaN 3 , then stained with 0.1% Coomassie blue R-250 in 40% methanol/10% acetic acid. Enzymes appeared as clear bands against a dark background of intact substrate, and the relative molecular weight of each band was estimated by comparing the migration positions of known molecularweight standards (Bio-Rad, Hercules, Calif) and a mixture of authentic MMP-9 and MMP-2 (gift of Howard Welgus, MD, Washington University School of Medicine).
In situ hybridization. Probes for in situ hybridization were prepared as described by Stahl-Backdahl et al. 16 In brief, a 190 base pair (bp) fragment of the 3' end of rat cox2 complementary DNA (cDNA; pMon 23916; Monsanto-Searle, St. Louis, Mo) and a 280 bp fragment of the 3' end of rat cox1 cDNA (pMon 23918; Monsanto-Searle, St. Louis, Mo) were subcloned in pGEM5Z transcription vectors (Promega, Madison, Wis) and then linearized. The RNA probes were transcribed from the linearized cDNA templates and labeled with digoxigenin-11-UTP under conditions recommended by and with reagents from Boerhringer Mannheim (Indianapolis, Ind). In situ hybridization was performed as described. 16 In brief, 5 µm tissue sections were treated with proteinase K (Sigma Chemical, St. Louis, Mo), washed in 0.1% mol/L triethanolamine buffer containing digoxigenin-labeled antisense or sense RNA probes, and incubated at 42°C for 18 hours in a humidified chamber. After hybridization, the slides were washed under stringent conditions, including treatment with ribonuclease-A. The sections were treated with alkaline phosphatase-conjugated antidigoxigenin antibody and 10% normal sheep serum, followed by 5-bromo-4-chl-3-indoyl phosphate and nitroblue tetrazolium as chromogens. After development for 4 to 24 hours in the dark, the color reaction was stopped with Milli-Q water, and the slides were stained with nuclear-fast red for final histologic analysis.
Statistical analysis. Comparisons among the aortic diameters for all three groups were made with analysis of variance. Comparisons between the elastase and the indomethacin groups were also made by means of a paired, two-tailed, Student t test.
RESULTS
The results of the aortic perfusion are depicted graphically in Fig 1. Aortic perfusion with saline did not result in any significant change in aortic diameter at any of the time points. In contrast, perfusion with elastase resulted in modest aortic dilation initially. The average aortic diameter in each group was 1.65 mm preperfusion. By day 2, both of the elastase groups showed aortic dilatation, with the aortic diameters of the elastase-only group being 2.43 ± 0.16 mm, as compared with 2.47 ± 0.11 mm in the indomethacin group (P > .05). The curves for aortic expansion remain essentially the same for both the elastase-only and the indomethacin groups through day 4 (Fig 1) , when aortic diameters were 2.73 ± 0.19 mm and 2.60 ± 0.20 mm (P > .05), respectively. However, by day 7, there was a marked divergence in average aortic diameters, with rapid aortic expansion in the elastaseonly group (3.87 ± 1.28 mm vs 2.81 ± 0.55 mm; P < .01). Aortic dilatation continued through day 14, with average aortic diameters of 5.27 ± 2.37 mm in the elastase-only group and 3.45 ± 1.11 mm in the indomethacin group (P = .01). In contrast, there was no aortic dilatation in the saline-only group. By day 28, no further aortic dilatation took place, and the final aortic diameters were actually slightly less than at day 14, with an average aortic diameter of 4.81 ± 1.70 mm in the elastase-only group, as compared with 3.18 ± 1.31 in the indomethacin group (P = .001).
The results of the PGE2 ELISA are depicted in Fig 2. Whole organ culture was performed on at least three aortas from each time point. In the control (saline-only) group, there was little variation in PGE2 synthesis above baseline. In contrast, the elastase-only group showed a sharp increase in PGE2 synthesis that paralleled aortic expansion, with synthesis markedly increasing on day 4 and peaking on day 14. Between days 14 and 28, PGE2 synthesis fell dramatically, while aortic dilatation stopped. In contrast, the rise in PGE2 synthesis in the indomethacin group was much less than that in the elastase-only group, as was aortic dilatation.
Substrate gel zymography was performed on media from the aortic organ cultures. The results showed that elastase perfusion, but not saline perfusion, was associated with increased MMP-9 activity. Treatment with indomethacin was associated with a marked decrease in MMP-9 expression ( Fig 3) .
By means of the results of the histological examination, treatment with elastase was demonstrated not to result in any marked changes in gross elastin architecture by day 4 (Fig 4) . However, after day 4, elastin destruction became quite pronounced, and by day 7, most elastic lamellae were severely damaged. By day 14, elastin destruction was nearly complete. The destruction of elastin coincided with the development of an intense inflammatory infiltrate. It also coincided with aortic dilatation. By day 28, inflammation had subsided, but by this time elastin destruction was essentially complete ( Fig 5) . In contrast, the indomethacin-treated aortas showed much less elastin destruction. Once again, elastin was intact through day 4. On day 7, there was evidence of elastin damage, but it was much less than that seen in the elastase-only group. Some elastin destruction continued through day 14, but at both day 14 and day 28, the aortas from the indomethacin-treated group maintained some elastin architecture.
PGE2 was demonstrated to be localized to mononuclear cells within the inflammatory infiltrate associated with the aortic wall by means of immunostaining. Similarly, cox2 was localized to these cells ( Fig 6) . PGE2 and cox2 were shown to be present in the macrophages within the inflammatory infiltrate by means of co-localization with immunostaining for macrophages. Little expression of cox1 was noted by means of immunostaining.
Similar findings to the immunohistochemistry with specific staining within macrophages for cox2 were demonstrated by means of in situ hybridization (Fig 7) . Very little cox1 expression was noted with in situ hybridization. Expression within macrophages was also shown by means of in situ hybridization for MMP-9. 
DISCUSSION
The effects of a nonspecific cyclooxygenase inhibitor, indomethacin, on an animal model of aortic aneurysms were investigated. It was shown that indomethacin markedly diminishes the aortic dilatation associated with elastase perfusion of the aorta, and its effects persist to 28 days. In untreated animals who underwent elastase perfusion, marked aortic dilatation occurred, beginning on day 4 and continuing through day 14, when the average aortic diameter was 5.27 mm or 319% of the normal aortic diameter. In the indomethacin-treated group, the average aortic diameter at day 14 was 3.45 mm or 209% of normal aortic diameter. Viewed another way, indomethacin prevented more than 50% of the aortic expansion associated with elastase perfusion. Aortic dilatation correlated with increased PGE2 expression, which began after day 4. This is the point at which aortic expansion began to occur. PGE2 synthesis peaked on day 14, which coincided with peak aneurysmal dilatation and subsequently subsided to baseline levels by day 28. By this time, aneurysm expansion had stopped and the inflammatory response had subsided. In animals treated with saline perfusion only, there was minimal aortic dilatation and little change in PGE2 synthesis. In the animals treated with indomethacin, PGE2 synthesis was markedly decreased, as compared with the elastase-only group; ie, decreased PGE2 synthesis correlated with decreased aneurysmal expansion and decreased MMP-9 activity. Furthermore, the cox2 isoform appeared to the predominant cyclooxygenase isoform, and its expression was localized to macrophages.
Although the effects of indomethacin are dramatic, they are not surprising. In human aneurysm disease, the initiating event is unknown, but medial and adventitial elastolysis have been implicated as early critical events. 17 AAAs have several salient features, including the destruction of the elastin elements of the aortic wall 18 and the presence of an inflammatory infiltrate that includes a large number of lymphocytes, plasma cells, and macrophages. 1 The model used in these experiments bears many similarities to the human condition. In the rat model, elastase perfusion is the event that starts the process of elastin degradation; ie, elastolysis is the initiating event. The time course of aneurysmal development correlates both to the development of an inflammatory infiltrate characterized by macrophages, lymphocytes, and neutrophils 13 and the induction of proteases. 19 Histologically, this model shows a strong resemblance to human AAAs, in that there is destruction of the structural elements of the aortic wall, particularly elastin. Interestingly, the initial injury with elastase results in only slight dilatation, but the subsequent inflammatory response and induction of proteases correlates with aneurysmal degeneration. 13, 19 This phenomenon was clearly seen in this experiment when aortic diameters remained relatively constant until day 4 postelastase perfusion in both the treated and untreated animals. Although the cause of the inflammatory response is unknown, it is likely caused by the elastin injury caused by the elastase. Elastin degradation products (EDPs) are chemotactic for inflammatory cells in vitro, as are other matrix degradation products. 20 Once elastin is injured, the EDPs initiate a series of events, ie, the recruitment of inflammatory cells, which lead to further destruction of the elastin and other structural elements of the extracellular matrix of the aorta.
Macrophages appear to be critical in this model. In fact, AAAs can be induced by the infusion of activated peritoneal macrophages and plasmin into the aorta. 12 Additional evidence implicating the inflammatory response in this model has been provided by several other studies. Dobrin documented that cyclosporin and methylprednisolone, both immunosuppressive Graphic representation of prostaglandin E 2 (PGE2) synthesis with time. Note that saline perfusion had little effect, whereas in the elastase-only and indomethacin groups, PGE2 synthesis mirrored aortic dilatation, with peak synthesis noted on day 14, when aortic dilatation was maximal. By day 28, PGE2 was nearly back to baseline, and all aortic dilatation had stopped. drugs, attenuated aneurysm growth in this model. 21 Ricci et al 22 demonstrated that treatment with a monoclonal antibody directed against the CD-18 leukocyte adhesion molecule also attenuated aneurysm growth and was associated with a marked decrease in the num-ber of infiltrating macrophages. Most recently, tumor necrosis factor binding protein, which inhibits the activity of the proinflammatory cytokine tumor necrosis factor, was shown to attenuate aneurysm growth when measured at the 6-day time point. 23
Fig 3.
Zymogram of aortic culture medium taken at day 14. On the right is a sample from a salineperfused aorta (saline), the next three lanes (elastase) are from the elastase-only group, and the last three lanes (Indo) are indomethacin-treated aortas. The band at 92 kDa represents matrix metalloprotease-9 (MMP-9). In the saline group, there is minimal MMP-9 activity. In the elastase-only group, there is significant lytic activity from MMP-9, and in the indomethacin group, MMP-9 activity is comparable to baseline. This indicates that indomethacin is associated with decreasing MMP-9 activity. Aortic tissue that has been stained with Verhoeff-van Gieson stain. The elastin fibers stain black within the media. Both micrographs were taken of aortas harvested on day 4. On the left is an elastase-only specimen, and on the right is a specimen from an animal treated with indomethacin. There is little difference in the architecture of the media between the two aortas at this point. May 1999 Macrophages have also been implicated in the pathogenesis of human AAAs. They are known to play an important role in regulating the turnover of extracellular matrix in both normal and pathologic conditions via the secretion of proteases including MMPs, protease inhibitors, and cytokines. MMPs, including MMP-2 and MMP-9, which are potent elastases, 24 are elevated in human AAA tissue and are believed to play a role in the pathogenesis of AAAs. [2] [3] [4] MMP-9 has been localized to macrophages in AAAs, 2, 3, 4 as has been urokinase, 25, 26 which synergistically enhances the ability of macrophages to destroy extracellular matrix. 27 Plasmin, the end product of urokinase activity and an activator of MMPs, is also elevated in AAA tissue. 28 When viewed together, these studies strongly suggest that macrophages are On the left is an elastase-only specimen that shows nearly complete loss of elastin fibers within the media. In the indomethacin-treated aorta, there is an obvious loss of elastin fibers within the media. In the indomethacin-treated aorta, there is obvious loss of elastin integrity, but much of the elastin is still intact, indicating that indomethacin helps minimize damage to elastin in this model. Photomicrograph from an elastase-treated aorta, harvested on day 14, that has been immunostained for cox2. Note the cell-specific hybridization within macrophages in the inflammatory infiltrate. participating in the pathogenesis of AAAs via a synergistic combination of MMPs, urokinase, and plasmin that degrades the matrix of the aorta.
Indomethacin worked in this experiment, even though it was given after the initiating event (elastase perfusion). This indicates that it is not necessary to prevent the initiating event, but only to intervene in a timely fashion. This is encouraging for the potential pharmacologic treatment of AAAs in humans. The initiating event or events are unknown, but it is a relatively simple matter to identify small AAAs. Currently, the management of small aneurysms (those smaller than 4.0 to 4.5 cm) is controversial, because the risk of rupture in the near future is low; however, the natural history is that more than 80% of small aneurysms will eventually require surgical intervention. 29 If an oral medication that inhibited aneurysm expansion with a good safety profile were available, it would be possible to treat small aneurysms pharmacologically. Unfortunately, NSAIDs, and therefore indomethacin, have significant adverse effects, such as peptic ulceration, platelet inhibition, and nephrotoxicity. These adverse effects are mediated by inhibition of the cox1 isoform of cyclooxygenase, whereas the anti-inflammatory effects are mediated by the cox2 isoform. 30, 31 Based on the data from this experiment and studies performed on human AAA organ cultures that documented that human AAA tissue synthesizes large quantities of PGE2 and expresses principally the cox2 isoform, 11 specific inhibition of cox2 alone would likely result in inhibition of aneurysm expansion. In fact, specific cox2 inhibitors have been developed. A recent study performed in rats using NS-398, a selective cox2 inhibitor, demonstrated that proinflammatory prostaglandin synthesis could be effectively blocked with this drug without the gastric ulcerogenic adverse effects that were seen with indomethacin in the same model. 32 Cox2 inhibitors are currently in clinical trial in humans and have minimal adverse effects. 33 If cox2 inhibitors prove to be safe, it may be possible to pharmacologically treat small aneurysms with minimal morbidity in the near future.
Dr Timothy Baxter (Omaha, Neb). This is really a nice piece of work. You've linked the cox2 gene and prostaglandin E 2 to the up-regulation of matrix metalloprotease-9 (MMP-9).
We've been interested in the possible role of MMP-2, and other studies have suggested that MMP-12 may be involved. Did you use zymography in any case to look at MMP-12 in this setting? It's also a macrophage product. Is it regulated in the same way as MMP-9?
Dr Jeffrey M. Reilly. We have not specifically looked at MMP-12. The work that Dr Robert Thompson has been doing at Washington University started a little bit after this. MMP-12 is something that we're currently looking at to see if there's an effect on its expression by indomethacin. It is certainly possible that this is one enzyme that is present. It's been shown in the work from Dr Thompson's laboratory that HME, or human macrophage elastase, is involved in abdominal aortic aneurysms in humans.
Dr Baxter. The drug companies have now developed the specific cox2 inhibitors. I'm sure you're aware of that. Has your laboratory started to look at those specific inhibitors to see how they do in this model? Dr Reilly. Yes, We have started to look at those, and according to the preliminary data-we haven't done all the biochemical analysis, but certainly on the basis of aortic dilatation-the cox2 inhibitors seem to have the same effect as indomethacin. We had some trouble in our animals with indomethacin's well-known adverse effect of peptic ulceration and perforation, and we haven't seen that in the cox2 inhibitor. (Chicago, Ill) . What human dose is comparable to the indomethacin used in your animals to obtain that degree of inhibition?
Dr William Pearce
Second, have you given a short pulse of the indomethacin at different times or stopped it at different times to see if this is continuous with your treatment? Dr Reilly. First, we picked the dose of indomethacin we use on the milligram-per-kilogram basis; it is the same dose that's used to treat humans with rheumatoid arthritis. So it's comparable to a human dose; it's not a suprapharmacologic dose.
Regarding the timing of treatment, one of the criticisms is always how easy it is to treat something if you start before they have an aneurysm, or whatever it is that one's looking at. In this case, it's important to emphasize that the animals were not pretreated with indomethacin. It was only given after the elastase perfusion. We believe that the elastase perfusion is the initiating event for the aneurysm formation.
However, we have gone out to the day-4 time point. We start treating a group of animals not at day 0, but at day 4, when the two curves are identical. If we start giving the indomethacin on day 4, the effect is still the same. So, even in this model, that's significantly after the initiating event, and the indomethacin is still effective.
We haven't gone out to the 7-day point and started giving indomethacin at 7 days to see if it stops the aneurysms from expanding at that point.
Dr John Hollett (Rochester, Minn). Those of us who are interested in pathogenesis of aneurysms know that this type of work will probably eventually lead to clinical trials, in which we look at these inhibitors. And one of the DISCUSSION potential problems with those trials will be that so many of our patients are already on nonsteroidals; they're on beta blockers; they're on other agents that may already be slowing the growth of aneurysms. And, in fact, as we look in our practice, we're impressed now with how many small aneurysms actually don't expand much with time.
In your clinical practice, have you looked at any clinical groups of patients, who are either on nonsteroidals or beta blockers, to see whether the expansion rate is less than what the literature previously reported? And have you looked at whether that might be problematic if we're thinking about clinical trials? Dr Reilly. No, we haven't looked specifically at patients on nonsteroidals to see if their aneurysm expansion rate is different. One of the problems is that most of the patients referred to us, as surgeons, are patients who already have aneurysms of operable size. I think that the initial studies that are going to be done with pharmacologic treatment might best target patients who have relatively large aneurysms, but who are a prohibitive risk for surgery. That might be the first place to start.
Identifying small aneurysms requires a big effort, and I think that trial will be done also, but will be more difficult to complete.
Dr Howard Greisler (Maywood, Ill). I think this is very elegant work, and you've really made a lot of progress with this model, but I'm concerned about the human extrapolation issue. In this model, clearly inflammatory mediators are important, macrophages are important, and apparently cox2 isoforms are important in prostaglandin and MMP production. However, you can suppress things for a short period very easily in animals, but not very effectively long term.
Do you think, for example, that for clinical use you would need to suppress the cox2 expression for years and years? Can that be done, given all the redundancy in the whole prostaglandin system? Dr Reilly. I don't know the answer to that question. I think you're right; if we're going to treat small aneurysms, it's going to have to be a long-term proposition.
Regarding the parallels between this model and the human model, at the biochemical level and the histologic level, there are a lot of similarities. Human aneurysms, at least at the stage at which we've been studying them, which is when they come to surgical attention, are characterized by intense inflammation. They have elevated levels of matrix metalloproteases in the wall. Those same things are seen in the animal model. Just as in human aneurysms, the animal models are characterized by destruction of the elastin elements of the aortic wall. So there are a lot of parallels between the two models. However, it's not perfect; our aneurysms stop growing at day 14, for example. The natural history of most human aneurysms is that they continue to grow. So I don't know what the difference is between the models.
However, it will require long-term treatment, and right now, one of the biggest drawbacks of using a drug such as indomethacin, one of the approved nonsteroidal inflammatory drugs, is that they don't have a great safety profile, particularly in elderly patients. They're associated with a significant incidence of peptic ulceration and nephrotoxicity, and there are the other recognized bleeding complications, caused by platelet inhibition.
The cox2 inhibitors, at least according to the preliminary data coming out of the phase 2 clinical trials in humans, have an outstanding safety profile. I think that it may be possible, as we learn more about these drugs, to keep a patient on those drugs for a long period.
